Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Blood tests may eventually reduce how often someone with cognitive decline needs an MRI or PET scan, but they aren’t ready to replace imaging entirely. These tests measure proteins released from the brain—like phosphorylated tau and amyloid-beta—that are associated with Alzheimer’s disease and other neurodegenerative conditions. For someone already diagnosed with dementia who returns for follow-up visits, a blood test might confirm that disease changes are progressing or stable, potentially delaying or avoiding the need for a full brain scan. However, blood tests and brain scans measure different things. An MRI shows the physical structure of your brain and can spot tumors, strokes, or unusual shrinkage patterns that a blood test cannot see.
A PET scan visualizes where amyloid and tau have accumulated throughout the brain. For now, these imaging studies remain essential for diagnosing dementia in the first place, even though blood biomarkers are improving rapidly. The real potential lies in selective use. A person with a confirmed dementia diagnosis might benefit from periodic blood work between imaging appointments, reducing unnecessary scans. Someone with memory complaints but no diagnosis still typically needs a brain scan to rule out other causes of cognitive loss.
Table of Contents
- Can Blood Tests Show Brain Changes Before an MRI Becomes Necessary?
- What Blood Tests Actually Measure vs. What Brain Imaging Shows
- Using Blood Tests in Clinical Monitoring: A Real-World Scenario
- Cost and Access: Where Blood Tests Offer Real Practical Advantages
- The Risk of False Reassurance from Normal Blood Test Results
- Research on Blood Tests for Different Types of Brain Changes
- When Repeated Brain Scans Are Still Necessary Despite Blood Tests
Can Blood Tests Show Brain Changes Before an MRI Becomes Necessary?
Blood biomarker tests have shown sensitivity to brain changes in research settings, sometimes detecting Alzheimer’s-related proteins years before a person experiences noticeable memory loss. This raises the possibility that a simple blood draw could serve as an early warning system, flagging who truly needs imaging. In principle, this could prevent unnecessary scans in people whose blood tests come back negative or stable. The caveat is significant: detecting a biomarker doesn’t always mean imaging is unnecessary.
Many people with abnormal Alzheimer’s biomarkers in their blood never develop dementia symptoms during their lifetime. A positive blood test tells you something has changed in the brain, but not whether that change will cause problems or when, which is information an MRI or cognitive assessment can help clarify. For someone with a family history of dementia, a negative blood test might offer reassurance and reduce scan frequency. For someone with early symptoms, a blood test might help guide whether imaging is truly urgent, but it typically cannot replace a first scan because it won’t show structural problems like a brain tumor or significant stroke.
What Blood Tests Actually Measure vs. What Brain Imaging Shows
Blood biomarker tests primarily measure proteins that leak from damaged brain cells into the bloodstream. The most-studied markers include phosphorylated tau (p-tau), which accumulates in Alzheimer’s disease, and amyloid-beta, which clumps in plaques. Some tests also measure neurofilament light chain (NfL), a protein released during broader neuronal injury from various conditions. These proteins indicate that something is happening inside the brain, but they don’t tell you the size, location, or severity of any damage. Brain imaging, by contrast, creates a visual map. An MRI shows whether the hippocampus (memory center) is shrinking, whether there are white matter changes, or whether an unexpected lesion is present.
A PET scan reveals exactly where amyloid and tau have deposited—knowledge that can inform treatment decisions and prognosis. A person might have high blood levels of tau but only mild changes on imaging, or vice versa; the two measurements don’t always correlate perfectly. This mismatch is a critical limitation. Some older adults show brain changes on MRI with no symptoms and no blood biomarker elevation. Others have biomarker-positive blood work but normal-looking brains on imaging. This variability means blood tests work best as a supplementary tool, not a substitute. In a scenario where someone’s doctor is deciding whether to repeat an MRI in a year or two, a blood test showing stable levels might delay imaging safely; a blood test showing rapid increases might prompt imaging sooner.
Using Blood Tests in Clinical Monitoring: A Real-World Scenario
Consider a 72-year-old woman diagnosed with mild cognitive impairment due to Alzheimer’s disease following an MRI and cognitive testing. At her first follow-up appointment three months later, her doctor might order a blood biomarker panel instead of repeating the expensive and time-consuming MRI. If the blood test shows stable tau and amyloid levels, it suggests her condition is not rapidly advancing, and she can safely continue her current treatment plan while her doctor reassesses clinically at the next visit. An MRI might be scheduled again in 12 months unless symptoms worsen.
If the blood test showed rapidly rising biomarkers, by contrast, the doctor might order imaging sooner to assess structural changes and consider whether medication adjustments are needed. This selective use of imaging based on blood biomarker trends could reduce the total number of brain scans a patient undergoes while maintaining safety. However, this approach works only for people already diagnosed. Someone presenting to a clinic with new memory problems still needs an initial brain scan to rule out stroke, tumor, or other reversible causes. No blood test alone can safely make that determination.
Cost and Access: Where Blood Tests Offer Real Practical Advantages
Blood tests cost significantly less than brain imaging and don’t require specialized equipment or a trip to a radiology center. For someone in a rural area or with limited mobility, a blood draw at a local clinic is far more feasible than traveling to an MRI facility. This advantage is real and meaningful, especially for repeat assessments. Access to specialized blood biomarker panels, however, varies widely by region and insurance coverage. Some panels are available through commercial laboratories; others remain largely research-focused and not widely accessible outside academic medical centers.
If a patient has access to neither blood testing nor regular MRI, the practical advantage disappears. A caregiver might choose to rely solely on clinical assessment and cognitive testing, which are low-cost and can be done in any office. The cost savings also depend on frequency. Replacing one MRI every two years with two or three blood tests annually is economical. Replacing monthly brain scans with monthly blood tests offers less advantage unless the blood tests genuinely enable treatment optimization that imaging could not provide.
The Risk of False Reassurance from Normal Blood Test Results
A negative or stable blood test can feel reassuring, but it carries a risk: a person might delay seeking imaging when they should pursue it. Someone with worsening memory problems who receives a normal blood biomarker result might assume no brain imaging is needed, when in fact an MRI is essential to rule out a treatable stroke or subdural hematoma. This risk is especially relevant for cognitive symptoms that emerge rapidly or change unexpectedly. If someone’s memory or language deteriorates noticeably over weeks, a blood test alone—however normal—should not prevent imaging.
Blood biomarkers reflect chronic changes linked to neurodegeneration, not acute events. Additionally, not all cognitive decline is caused by Alzheimer’s pathology. Vascular dementia, frontotemporal dementia, Lewy body disease, and other conditions have different biomarker profiles or don’t show up strongly in blood work at all. A normal amyloid and tau panel doesn’t rule out these alternatives; imaging does.
Research on Blood Tests for Different Types of Brain Changes
Emerging research is expanding blood biomarkers beyond Alzheimer’s pathology. Markers for phosphorylated tau with different structural variants may help distinguish Alzheimer’s from frontotemporal dementia, and neurofilament light chain is being studied in Parkinson’s disease, ALS, and multiple sclerosis.
These developments could eventually allow blood tests to provide diagnostic hints about the type of neurodegeneration occurring. In specialized memory clinics, some centers now use blood biomarker testing alongside cognitive testing to narrow the differential diagnosis before ordering imaging. This can reduce the number of unnecessary scans in people whose blood results point clearly toward a specific condition.
When Repeated Brain Scans Are Still Necessary Despite Blood Tests
Certain situations require repeated imaging even if blood biomarkers are available. Someone on a new dementia medication might need follow-up MRIs to check for rare side effects or unexpected changes. A person showing significant cognitive decline despite stable biomarkers needs imaging to investigate why—possibly uncovering a treatable condition like normal pressure hydrocephalus.
And anyone with worsening symptoms that don’t match their baseline needs imaging to ensure no new problem has developed. Treatment research studies often require repeated imaging regardless of blood results, because the research question may focus on how structural changes evolve over time. For these scenarios, blood tests add useful information but don’t replace imaging protocols. The combination of both tools provides more complete information than either alone.
- —
